ERBB2 and breast carcinoma: The combination of lapatinib with capecitabine has been approved for treating advanced or metastatic HER2-positive breast cancer patients who have progressed following standard therapy, including anthracyclines, taxanes, and trastuzumab (de Azambuja et al., 2014).